AN2 THERAPEUTICS INC (ANTX) competitors & alternatives
Health Care · NASDAQ
AN2 THERAPEUTICS INC (ANTX)'s top competitors and alternatives — its most similar public companies — include Insmed (INSM), ATEA PHARMACEUTICALS INC (AVIR), SEPTERNA INC (SEPN), OMEROS CORP (OMER), TONIX PHARMACEUTICALS HOLDING CORP (TNXP), SPRUCE BIOSCIENCES INC (SPRB), GALECTIN THERAPEUTICS INC (GALT), AQUESTIVE THERAPEUTICS INC (AQST), SOLID BIOSCIENCES INC (SLDB), SAVARA INC (SVRA), XERIS BIOPHARMA HOLDINGS INC (XERS) and DAMORA THERAPEUTICS INC (DMRA). These are AN2 THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ANTX competitors & alternatives
-
InsmedINSMHealth Care
A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in…
$106.64 (as of 2026-07-22) · market cap $23.4B
-
ATEA PHARMACEUTICALS INCAVIRHealth Care
A clinical-stage antiviral company advancing pan-genotypic HCV and HEV therapies toward FDA submissions, leveraging proprietary nucleoside/nucleotide chemistry…
$4.81 (as of 2026-07-22) · market cap $385M
-
SEPTERNA INCSEPNHealth Care
An early-stage biotech company developing cell receptor-targeted therapeutics for inflammation, metabolism, and other diseases through its proprietary…
$34.20 (as of 2026-07-22) · market cap $1.5B
-
OMEROS CORPOMERHealth Care
A clinical-stage biotech company commercializing complement-pathway inhibitors for rare hematologic and immune diseases, with FDA-approved YARTEMLA for stem…
$9.84 (as of 2026-07-22) · market cap $703M
-
TONIX PHARMACEUTICALS HOLDING CORPTNXPHealth Care
A fully-integrated biopharmaceutical company commercializing TONMYA (cyclobenzaprine sublingual tablets) for fibromyalgia while advancing a pipeline of CNS,…
$10.59 (as of 2026-07-22) · market cap $184M
-
SPRUCE BIOSCIENCES INCSPRBHealth Care
Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo…
$44.60 (as of 2026-07-22) · market cap $123M
-
GALECTIN THERAPEUTICS INCGALTHealth Care
Clinical-stage biopharmaceutical company developing galectin-3 inhibitors derived from plant carbohydrates to treat liver fibrosis, cirrhosis, and cancer.
$3.50 (as of 2026-07-22) · market cap $253M
-
AQUESTIVE THERAPEUTICS INCAQSTHealth Care
Aquestive develops orally disintegrating film formulations for CNS disorders, acute seizures, and opioid use, leveraging proprietary sublingual and buccal film…
$3.94 (as of 2026-07-22) · market cap $496M
-
SOLID BIOSCIENCES INCSLDBHealth Care
A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's…
$8.10 (as of 2026-07-22) · market cap $808M
-
SAVARA INCSVRAHealth Care
Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
$5.65 (as of 2026-07-22) · market cap $1.2B
-
XERIS BIOPHARMA HOLDINGS INCXERSHealth Care
A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug…
$8.38 (as of 2026-07-22) · market cap $1.5B
-
DAMORA THERAPEUTICS INCDMRAHealth Care
Damora Therapeutics is a biotechnology company developing a pipeline of precision antibody therapies specifically targeting mutCALR-driven myeloproliferative…
$29.99 (as of 2026-07-22) · market cap $1.8B
Not quite? Describe exactly what you want →
Peers are AN2 THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: AN2 THERAPEUTICS INC (ANTX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.